Sign in
AGLE Stock Price, Chart, Stats & News
Aeglea BioTherapeutics, Inc.
Save
48.63M
Market cap
–
Current P/E
–
Forward P/E
AGLE chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.01% |
ROA | -19.95% |
ROE | -29.44% |
D/E | – |
Interest coverage ratio | – |
AGLE valuation
P/E | – |
P/S | – |
P/B | 5.81x |
P/CF | -24.56x |
P/FCF | -0.29x |
P/OCF | -24.56x |
PEG | 0.11x |
EV multiple | -0.79x |
About
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating human enzyme therapies for rare metabolic diseases. Their leading candidate, pegzilarginase, a recombinant human Arginase 1, is currently in the pivotal Phase III PEACE trial to assess its safety and effectiveness for treating Arginase 1 deficiency. Furthermore, the company is developing AGLE-177, a polyethylene glycol modified enzyme, which is progressing through Phase I/II clinical trials for homocystinuria.
Similar securities
Based on sector and market capitalization
Report issue